Listen to Catherine Hall, VP of Product Strategy at endpoint Clinical as she discusses virtual trials and direct-to-patient logistics with Michael MacNeir, VP Commercial Operations North America at Marken. During the disruption of site-based trials due to COVID-19, the pharmaceutical industry is reexamining virtual trials and direct-to-patient logistics. Regulatory changes are enabling the industry to reshape direct-to-patient logistics, thus making virtual trials possible on a larger scale. Find out the benefits, challenges, and considerations in direct-to-patient trials that early adopters have overcome by implementing virtual and hybrid trials.
What you’ll learn:
- Gain an understanding and the benefits of virtual and hybrid trials
- Gain insights into direct-to-patient logistics and have a better understanding of challenges that may be faced and how to resolve them
- See how leveraging technology will help solve challenges today and for the future of clinical trial management
Catherine Hall, VP of Product Strategy, endpoint Clinical
Cat Hall started her career as an academic scientist in Molecular and Cellular Biology before finishing her MBA and transitioning into Pharmaceutical Supply Chain Management. During her career, she developed notable expertise not only in clinical supplies but also in training development, process improvement, managing partnerships, and the design and implementation of technologies such as Interactive Response Technology (IRT). She is well-known for focusing on bridging the GMP/GCP gap by bringing supply chain customer service through the last mile to patients. Cat joined endpoint in 2019 as VP of Product Strategy to help continue to bring the customer voice forward into shaping the future of IRT.
Michael MacNeir, VP Commercial Operations North America, Marken
Michael MacNeir is a leader in Marken’s Commercial Operations team. Michael currently has over 11 years of experience in the Pharmaceutical and Life Science Industries with strong experience in decentralized models and supply chain. His peers and clients find him to be focused on individual client’s needs and project-focused with innovative ideas and solutions to overcome challenges within the clinical supply chain.
He came to Marken as Director of Commercial Operations and quickly became the Subject Matter Expert for Marken Direct-to-Patient services globally. He currently manages the US sales team.